Nymox Pharmaceutical Corporation (NYMXF)

Market Cap	10.29M
Revenue (ttm)	n/a
Net Income (ttm)	-8.84M
Shares Out	93.54M
EPS (ttm)	-0.10
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1
Open	0.100
Previous Close	n/a
Day's Range	0.100 - 0.110
52-Week Range	0.000 - 1.400
Beta	0.31
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 14, 2024

About Nymox Pharmaceutical

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of products for the aging population in Canada, the United States, and Europe. Its lead drug candidate is Fexapotide Triflutate (NX-1207) for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as hepatocellular carcinoma. The company also offers NicAlert for detecting smoking status; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1989
• Employees: 16
• Stock Exchange: OTCMKTS
• Ticker Symbol: NYMXF